Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for VRTX
+0.03 (0.02%)
After Hours: 125.16 +0.08 (0.06%)
May 22, 4:49PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 124.33 - 125.96
52 week 63.68 - 137.50
Open 124.91
Vol / Avg. 1.17M/1.63M
Mkt cap 30.51B
P/E     -
Div/yield     -
EPS -2.95
Shares 243.75M
Beta 0.35
Inst. own 97%
Jul 27, 2015
Q2 2015 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 4, 2015
Vertex Pharmaceuticals Inc Annual Shareholders Meeting - 9:30AM EDT - Add to calendar
May 19, 2015
Vertex Pharmaceuticals Inc at UBS Global Healthcare Conference
Apr 29, 2015
Q1 2015 Vertex Pharmaceuticals Inc Earnings Call - Webcast
Apr 29, 2015
Q1 2015 Vertex Pharmaceuticals Inc Earnings Release
Mar 3, 2015
Vertex Pharmaceuticals Inc at Cowen Health Care Conference
Feb 24, 2015
Vertex Pharmaceuticals Inc at RBC Healthcare Conference
Feb 23, 2015
Vertex Pharmaceuticals Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -143.46% -127.81%
Operating margin -124.17% -119.30%
EBITD margin - -99.62%
Return on average assets -35.42% -31.88%
Return on average equity -77.66% -60.68%
Employees 1,830 -
CDP Score - -


50 Northern Ave
BOSTON, MA 02210-1862
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated engages in the discovery, development, manufacture, and commercialization of small molecule drugs for patients with serious diseases in specialty markets. The Company markets KALYDECO in the United States and international markets for the treatment of patients six years of age and older with cystic fibrosis (CF), who have a specific genetic mutation in their CF transmembrane conductance regulator (CFTR), gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. The Company’s business is focused on developing and commercializing therapies for the treatment of CF and advancing its other research and early-stage development programs.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David Altshuler M.D., Ph.D. Executive Vice President - Global Research, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Executive Vice President - Global Government Strategy, Market Access and Value
Age: 47
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 48
Bio & Compensation  - Reuters
Bruce I. Sachs Co-Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Elaine S. Ullian Co-Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Joshua S. Boger Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters